Epipodophyllotoxin-Related Myelodysplastic Syndrome

A disorder seen following cancer chemotherapy. It typically manifests a few years after initiation of epipodophyllotoxin chemotherapy. Mutagenic potential of these non-intercalating DNA topoisomerase II inhibitors is believed to be increased with concurrent use of asparaginase or granulocyte colony-stimulating factor. Balanced translocations involving chromosomal bands 11q23 and 21q22 are commonly associated with this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course usually progresses to acute myeloid leukemia though most epipodophyllotoxin-related leukemias do not have an antecedent myelodysplastic phase. Prognosis is dismal with survivability usually less than one year. (NCI Thesaurus)

YOU MAY ALSO LIKE

Epipodophyllotoxin Compound

An alkaloid isolated or derived synthetically from Podophyllum peltatum that can bind to and inhibit topoisomerase II and its function in ligating…

Epipodophyllotoxin

A substance being studied in the treatment of some types of cancer. Epipodophyllotoxin is extracted from the mandrake root Podophyllum peltatum. It…

Epiphysis of the Bone

The round end of the long bones.

Epinephrine-Secreting

A finding indicating that an excess amount of epinephrine is secreted by a tumor.

Epinephrine Secretion Inhibition

Epinephrine Secretion Inhibition consists of interference with, or restraint of, activities involved in release across the cell membrane into the bloodstream from…

Epinephrine Secretion Induction

Epinephrine Secretion Induction consists of the initiation of activities involved in release across the cell membrane into the bloodstream from the adrenal…